Results Published from STRONG Trial of Zolgensma
Information
Information
Conversations with health professionals – new webinar!
SEND and Alternative Provision Improvement Plan published
Interim Results from Risdiplam Jewelfish Trial Published
NHS England agrees to allow access to Sapphire Trial to enhance treatments for SMA
England’s Managed Access Agreement for Nusinersen extended to July 2025
Scholar Rock presents latest TOPAZ Trial data at the international scientific congress on SMA
Food and Drug Administration (FDA) in U.S. approves Evrysdi® (Risdiplam) to include babies under 2 months old with SMA
